Search results for "remission"

showing 10 items of 213 documents

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group stu…

2005

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often become a subject of debate because of regeneration more than 5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary. This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols. Patients with < or =5% blasts showed the best overall survival (OS) and the lowest relapse risk …

AdultMaleRiskmedicine.medical_specialtyPathologyAdolescentcomplete remissionMINIMAL RESIDUAL DISEASEDIAGNOSISGastroenterologyTHERAPYDisease-Free SurvivalAMLRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPlateletacute myeloid leukaemiaLymphocyte CountProportional Hazards ModelsrevisedHematologycriteriaProportional hazards modelbusiness.industryINDUCTIONRemission InductionCancerHematologyMiddle AgedCOLONY-STIMULATING FACTORmedicine.diseaseMinimal residual diseaseCANCERHIGH-DOSE CYTARABINELeukemiamedicine.anatomical_structureLeukemia MyeloidAcute DiseaseFemaleBone marrowbusinessBritish Journal of Haematology
researchProduct

Spontaneously‐resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and cli…

2018

It has been reported that low-plasma cytomegalovirus (CMV) DNA loads are associated with an increased risk of overall mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Utilizing a conservative strategy for initiation of preemptive antiviral therapy (>1500 IU/mL), we characterized the virological features of spontaneously-resolving episodes of CMV DNAemia and assessed their impact on mortality through the first year after transplantation. We reviewed the CMV DNA polymerase chain reaction results and clinical charts of 230 consecutive adult patients who underwent T-cell replete allo-HSCT at our center. A total of 280 episodes of CMV DNAemia were registered in 164 pa…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRemission SpontaneousCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineHumansTransplantation HomologousIn patient030212 general & internal medicineAgedRetrospective Studiesbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCmv dnaemiaMiddle AgedViral Loadmedicine.diseaseVirologyTransplant RecipientsConservative strategyTransplantationInfectious DiseasesIncreased riskCytomegalovirus InfectionsDNA ViralFemale030211 gastroenterology & hepatologyAllogeneic hematopoietic stem cell transplantbusinessJournal of Medical Virology
researchProduct

Pancreatic encephalopathy: a 7-year follow-up case report and review of the literature

2003

Pancreatic encephalopathy is a rare complication of acute pancreatitis. Clinical features include focal neurological signs and acute onset of dementia. This picture can fluctuate over time: cyclic progression with remission and relapses has been described. We present the case of a 43-year-old man who, after an acute episode of pancreatitis, experienced five relapses, with alternating focal signs. The patient has improved, but cognitive impairment persists after a 7-year follow-up.

AdultMalePediatricsmedicine.medical_specialtyNeurologyRemission SpontaneousEncephalopathyDermatologyNeuropsychological TestsDiagnosis DifferentialRecurrencemedicineHumansDementiaNeuroradiologyBrain Diseasesbusiness.industryElectrodiagnosisGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingSurgeryParesisPsychiatry and Mental healthPancreatitisAcute DiseaseAmylasesChronic DiseaseDisease ProgressionAcute pancreatitisPancreatitisAtaxiaNeurology (clinical)NeurosurgeryCognition DisordersComplicationbusinessFollow-Up StudiesNeurological Sciences
researchProduct

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

2015

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number was 2. No formal dose-limiting toxicity was observed. Dominant non-hematological side effects were fatigue in 11 (73%), nausea in 9 (60%), mucositis in 7 (47%) and vomiting in 6 patients (40%). Coug…

MaleBendamustineCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseFollicular lymphomaLymphoma Mantle-CellNeutropeniaGastroenterologyAntibodies Monoclonal Murine-Derivedhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisBendamustine HydrochlorideHumansProspective StudiesLymphoma FollicularAgedNeoplasm StagingSirolimusLeukopeniabusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseTemsirolimusSurgerySurvival RateOncologyNitrogen Mustard CompoundsFeasibility StudiesFemaleMantle cell lymphomaRituximabNeoplasm Recurrence LocalSafetymedicine.symptomRituximabbusinessFollow-Up Studiesmedicine.drugLeukemia
researchProduct

A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer pat…

2019

Purpose Cancer treatments often produce undesirable side-effects, such as skin toxicity, impacting on everyday functioning and health-related quality of life (HRQoL). This experimental study sought to determine whether aesthetic products and treatments could significantly decrease perceived skin symptoms, psychological distress and improve skin-related QoL (SRQoL). Methods An experimental group composed of 100 breast patients was enrolled for specialized aesthetic treatments at the European Institute of Oncology (IEO) and compared to a control group of 70 breast patients who did not receive any aesthetic treatment. A measure of SRQoL (i.e., Skindex-16) and a distress thermometer were admini…

Quality of lifemedicine.medical_specialtyEstheticsBreast NeoplasmsPilot ProjectsSettore M-PSI/08 - PSICOLOGIA CLINICAAesthetic treatmentArticle03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifemedicineDistress ThermometerHumansSurgery PlasticCancer treatmentsHealth related quality of lifebusiness.industry030503 health policy & servicesPublic Health Environmental and Occupational HealthComplete remissionCancerSkin toxicityMiddle Agedmedicine.diseaseSkin symptomsHealth psychologyDistress030220 oncology & carcinogenesisPhysical therapyFemale0305 other medical sciencebusinessQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
researchProduct

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of …

2017

Abstract The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn’s disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.

medicine.medical_specialtyIBDDiseaseGuidelineGuidelinesInflammatory bowel diseaseGastroenterologyBiological drugs03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineMedicalmedicineCorticosteroidCorticosteroidsHumansIn patient030212 general & internal medicineCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Hepatology; GastroenterologySocieties MedicalCrohn's diseaseSettore MED/12 - GastroenterologiaUlcerative colitiHepatologybusiness.industryImmunosuppressorsRemission InductionGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesClinical PracticeCrohn's diseaseUlcerative colitisItalyImmunosuppressorCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Adrenal Cortex Hormones; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Italy; Remission Induction; Societies Medical030211 gastroenterology & hepatologybusinessSocietiesImmunosuppressive Agents
researchProduct

Prognosis of migraine headaches in adolescents: a 10-year follow-up study.

2006

Objective: To determine the long-term outcome of migraine headaches in adolescents and to identify possible predictors of prognosis. Methods: Fifty-five of 80 subjects with migraine headaches (ages 11 to 14 years), who attended the baseline examination of a population-based study conducted in southern Italy in 1989, were eligible for follow-up in 1999. All interviews and examinations were conducted by neurologists, and migraine diagnoses were based on the International Headache Society (IHS) criteria. The association between possible prognostic factors and the long-term persistence of migraine headaches was explored using logistic regression analysis. Results: Of 55 subjects with migraine h…

MaleMigraine without AuraRiskmedicine.medical_specialtyPediatricsTime FactorsAdolescentAuraMigraine DisordersMigraine with AuraRemission SpontaneousPopulationLogistic regressionMedical RecordsAge DistributionOutcome Assessment Health CareOdds RatiomedicineHumansProspective StudiesSex DistributionFamily historyChildeducationeducation.field_of_studybusiness.industry10 year follow upTension-Type HeadacheOdds ratioPrognosismedicine.diseaseLogistic ModelsMigraineMigraine prognosis headacheChronic DiseasePhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)Headachesmedicine.symptombusinessFollow-Up Studies
researchProduct

Impaired conflict resolution and vigilance in euthymic bipolar disorder.

2015

Abstract Difficulty attending is a common deficit of euthymic bipolar patients. However, it is not known whether this is a global attentional deficit or relates to a specific attentional network. According to the attention network approach, attention is best understood in terms of three functionally and neuroanatomically distinct networks-alerting, orienting, and executive control. In this study, we explored whether and which of the three attentional networks are altered in euthymic Bipolar Disorder (BD). A sample of euthymic BD patients and age-matched healthy controls completed the Attention Network Test for Interactions and Vigilance (ANTI-V) that provided not only a measure of orienting…

AdultMalemedicine.medical_specialtyBipolar Disordermedia_common.quotation_subjectAudiologyalerting; attention network test (ant); bipolar disorders; executive control; orienting; vigilance; psychiatry and mental health; biological psychiatryExecutive Functionbiological psychiatryvigilanceOrientationConflict resolutionattention network test (ant)medicineReaction TimeHumansAttentionBipolar disordermedia_commonNegotiatingorientingAttentional controlComplete remissionIndependent measureCognitionMiddle Agedmedicine.diseaseFunctional recoverypsychiatry and mental healthAffectexecutive controlbipolar disordersalertingFemalePsychologyArousalCognitive psychologyVigilance (psychology)Psychiatry research
researchProduct

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

2021

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 3…

OncologyAdultCancer Researchmedicine.medical_specialtyreal-world*real-world03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy Protocolsmedicine*FLT3mut AMLHumansPatterns of carerelapseSalvage TherapyAdult patientsFLT3mut AMLbusiness.industryFLT3mut AML real-world relapse/refractoryRemission InductionCytarabineMyeloid leukemiaHematology*relapse/refractoryrefractoryLeukemia Myeloid AcuteTreatment OutcomeOncologyfms-Like Tyrosine Kinase 3030220 oncology & carcinogenesisRelapsed refractorybusiness030215 immunologyLeukemialymphoma
researchProduct

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.

1989

Recent preclinical and clinical studies that have demonstrated antitumor activity of high-dose recombinant interleukin-2 (rIL-2), and animal models that demonstrated a synergistic effect of low-dose cyclophosphamide, led us to study rIL-2 (Cetus Corp., Emeryville, Calif) in a phase II clinical trial in combination with low-dose cyclophosphamide in 32 patients, 18 with malignant melanoma and 14 with renal cell carcinoma. rIL-2 was given once daily at 3 x 10(6) U/m2, as a 30-min infusion for 14 days in cycle I and for 2 x 5 days in cycles II and III respectively; if tolerated, the dose was increased to a maximum of 6 x 10(6) U m-2 day-1; the cycles, separated by 1 week treatment-free interval…

Interleukin 2AdultMaleCancer Researchmedicine.medical_specialtyPathologyCyclophosphamidemedicine.medical_treatmentImmunologyPhases of clinical researchGastroenterologyDrug Administration ScheduleRenal cell carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineHumansNeoplasm MetastasisCyclophosphamideMelanomaAgedChemotherapyKidneybusiness.industryMelanomaCarcinomaRemission InductionReceptors Interleukin-2Middle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsBlood Cell Countmedicine.anatomical_structurePhenotypeOncologyDrug EvaluationInterleukin-2FemaleBolus (digestion)businessmedicine.drugCancer immunology, immunotherapy : CII
researchProduct